Vanda Pharmaceuticals | VNDA - Чистый доход





Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
AstraZeneca USD 3.08B 754M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -328.48M 41.54M 2025-12
J&J USD 5.24B 119M 2026-03
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Moderna USD -1.34B 517M 2026-03
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR 1.61B 2.42B 2026-03
Takeda JPY 103.64B 115.44B 2025-12
Teva Pharmaceutical Industries USD 369M 111M 2026-03
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Veracyte USD 41.15M 22.01M 2025-12